Pharmaceutical Technology3d
Health Canada approves GSK’s Ojjaara for myelofibrosis in anaemia patients
GSK added Ojjaara to its portfolio through the acquisition of Sierra in 2022. Credit: Magda Wygralak via Shutterstock. Health ...
Daily2d
GSK Ojjaara approved in Canada for treatment of myelofibrosis in adults who have moderate to severe anemia
Mississauga: GSK has announced that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...
Ojjaara (momelotinib) approved in Canada for the treatment of myelofibrosis in adults who have moderate to severe anemia
CNW/ - GSK announced today that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...
Pharmabiz3d
Health Canada approves GSK’s Ojjaara for the treatment of myelofibrosis in adults who have moderate to severe anaemia
Mississauga, Ontario Thursday, November 14, 2024, 09:00 Hrs [IST] ...
Here’s How Jakafi’s Patent Expiry Impacts Incyte Corporation’s (INCY) Growth Prospects
Many investors continue to be worried about Incyte’s financial prospects when the patent for the company’s blood cancer ...
Business Wire3d
Opna Bio Announces 2024 ASH Presentations Highlighting Interim Data from Phase 1 Combo Study of BET Inhibitor OPN-2853 with Ruxolitinib in Myelofibrosis, and Promising ...
Investigator-sponsored study Title: “PROMise Trial: Interim analysis of PROMise, a clinical study combining the BET inhibitor OPN-2853 with ruxolitinib in patients with advanced myelofibrosis ...
news.stv1d
Donor appeal: 'Thought that I might not be here for my daughter is terrifying'
Rachael Nixon desperately needs to find a stem cell donor, after being diagnosed with a rare and aggressive form of blood ...
The American Journal of Managed Care2d
Studies Highlight Prognostic Value of Neutrophil-to-Lymphocyte Ratio in MPNs
Neutrophil-to-lymphocyte ratio (NLR) is a significant prognostic indicator in myeloproliferative neoplasms, correlating with ...
GlobalData on MSN5d
Disc Medicine secures $200m financing to support trials
The loan facility comprises up to four tranches, with a $30m tranche already drawn at closing and further funds available ...
EurekAlert!4d
Sylvester Cancer researchers share findings in oral presentations at the ASH 2024 Annual Meeting & Exposition
Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained ...
ETF Daily News3d
Janney Montgomery Scott LLC Lowers Stake in Incyte Co. (NASDAQ:INCY)
The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and ...
Le Lézard3d
Kidneyhood.org Publishes "The Evidence-Based Guide to Kidney and Renal Diets": The First Comprehensive Resource for Dietary Kidney Disease Management
This investment is in... at 09:20 Opna Bio Announces 2024 ASH Presentations Highlighting Interim Data from Phase 1 Combo Study of BET Inhibitor OPN-2853 with Ruxolitinib in Myelofibrosis, and ...